SGHT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sight Sciences Inc (SGHT) is not a strong buy for a beginner, long-term investor at the moment. While the company has potential growth catalysts in its Dry Eye segment and improving gross margins, the stock is currently in a downtrend with significant insider selling and weak technical indicators. The lack of recent Intellectia Proprietary Trading Signals further supports a cautious approach.
The stock is in a bearish trend with a regular market price drop of -7.83%. The RSI at 17.52 indicates an oversold condition, but the MACD histogram is negative and expanding downward, suggesting continued bearish momentum. The stock is trading near its S2 support level of 3.485, indicating potential further downside risk.
Strong gross margins of 87.26% in Q4
Projected 2026 revenue growth between $82M and $88M.
Positive sentiment from analysts regarding the TearCare opportunity and Medicare fee schedule establishment.
Significant insider selling, with a 4122.05% increase in the last month.
Weak technical indicators, including negative MACD and oversold RSI.
Lowered price targets from UBS and Citi, reflecting cautious sentiment.
Net income and EPS dropped significantly YoY in Q4 2025.
In Q4 2025, revenue increased by 6.87% YoY to $20.39M, but net income dropped by 64.87% YoY to -$4.16M. EPS also declined by 65.22% YoY to -$0.08. Gross margins improved slightly to 87.26%, indicating operational efficiency despite higher operating expenses.
Analysts have mixed views. UBS and Citi recently lowered their price targets to $11 and $6.50, respectively, while Stifel raised its target to $8. Analysts remain optimistic about the TearCare opportunity but cautious about the surgical glaucoma segment.
